论文部分内容阅读
目的检测ALCAM在胃癌组织中表达的情况,探讨其与临床病理参数的关系及对胃癌预后的临床意义。方法应用免疫组织化学方法检测61例胃癌组织中ALCAM的表达情况并分析ALCAM与胃癌临床病理特征及预后的关系。结果 ALCAM在胃癌组织中的阳性表达率明显高于癌旁组织,癌旁组织未见表达。TNM分期Ⅲ+Ⅳ期、伴淋巴结转移者癌组织中ALCAM表达明显高于对应组,而与患者的年龄、性别、术前CEA水平、肿瘤部位、肿瘤大小无关。单因素分析显示术前TNM分期、淋巴结转移、分化程度、ALCAM与胃癌患者总生存期相关;COX风险模型提示TNM分期、淋巴结转移、ALCAM为胃癌总体生存时间预后的独立危险因素。结论 ALCAM可能参与胃癌发展的恶性进程,其高表达提示胃癌患者预后不良。
Objective To detect the expression of ALCAM in gastric carcinoma and to investigate the relationship between the expression of ALCAM and clinicopathological parameters and the clinical significance of prognosis of gastric carcinoma. Methods The expression of ALCAM in 61 cases of gastric carcinoma was detected by immunohistochemistry and the relationship between ALCAM and the clinicopathological features and prognosis of gastric carcinoma was analyzed. Results The positive expression rate of ALCAM in gastric cancer tissues was significantly higher than that in paracancerous tissues, but not in adjacent tissues. The expression of ALCAM in TNM stage Ⅲ + Ⅳ stage with lymph node metastasis was significantly higher than that in corresponding group, but not with age, sex, preoperative CEA level, tumor location and tumor size. Univariate analysis showed preoperative TNM staging, lymph node metastasis, degree of differentiation, and ALCAM were associated with overall survival in patients with gastric cancer. The COX risk model suggested that TNM staging, lymph node metastasis and ALCAM were independent prognostic factors for the overall survival of gastric cancer. Conclusion ALCAM may be involved in the malignant progression of gastric cancer. The high expression of ALCAM suggests that gastric cancer patients have poor prognosis.